Results 71 to 80 of about 6,680,139 (200)

Optimization and validation of a virus‐like particle pseudotyped virus neutralization assay for SARS‐CoV‐2

MedComm
Spike‐protein‐based pseudotyped viruses were used to evaluate vaccines during the COVID‐19 pandemic. However, they cannot be used to evaluate the envelope (E), membrane (M), and nucleocapsid (N) proteins. The first generation of virus‐like particle (VLP)
Shuo Liu, Li Zhang, Wangjun Fu, Ziteng Liang, Yuanling Yu, Tao Li, Jincheng Tong, Fan Liu, Jianhui Nie, Qiong Lu, Shuaiyao Lu, Weijin Huang, Youchun Wang   +12 more
doaj   +1 more source

N-terminally myristoylated feline foamy virus Gag allows Env-independent budding of sub-viral particles [PDF]

, 2011
Foamy viruses (FVs) are distinct retroviruses classified as Spumaretrovirinae in contrast to the other retroviruses, the Orthoretrovirinae. As a unique feature of FVs, Gag is not sufficient for sub-viral particle (SVP) release. In primate and feline FVs (
Löchelt, Martin, Martin Löchelt, Yong-Boum Kim, Liu, Yang, Yang Liu, Kim, Yong-Boum   +5 more
core   +1 more source

A Viral Platform for Chemical Modification and Multivalent Display

Journal of Nanobiotechnology, 2003
The ability to chemically modify the surfaces of viruses and virus-like particles makes it possible to confer properties that make them potentially useful in biotechnology, nanotechnology and molecular electronics applications. RNA phages (e.g. MS2) have
Peabody David S
doaj   +1 more source

Development of Virus-like Particle Plant-Based Vaccines against Avian H5 and H9 Influenza A Viruses [PDF]

Avian influenza A virus (AIV) is a significant cause of mortality in poultry, causing substantial economic loss, particularly in developing countries, and has zoonotic potential.
Iqbal, Munir, Dunham, Stephen P., Elbohy, Ola A, Janet M. Daly, Stephen P. Dunham, Daly, Janet M., Munir Iqbal, Dunham, Stephen P, Elbohy, Ola A., Daly, Janet M, Ola A. Elbohy   +10 more
core   +1 more source

Virus-like particles in vaccine development

Expert Review of Vaccines, 2010
Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and ...
António, Roldão, Maria Candida M, Mellado, Leda R, Castilho, Manuel J T, Carrondo, Paula M, Alves   +4 more
openaire   +2 more sources

Optineurin negatively regulates the induction of IFNβ in response to RNA virus infection [PDF]

, 2010
The innate immune response provides a critical defense against microbial infections, including viruses. These are recognised by pattern recognition receptors including Toll-like receptors (TLRs) and RIG-I like helicases (RLHs).
Harris, M., Macdonald, A., Kohl, A., Richards, KH, Wetherill, L, Kohl, Alain, MacDonald, A, Mankouri, Jamel, Kohl, A, Elliott, Richard M., Elliott, RM, Alain Kohl, Wetherill, L.F., Rennos Fragkoudis, Harris Mark, Andrew Macdonald, Richards Kathryn H., Richards, K.H., Richards, K, Laura F Wetherill, Mankouri, J., Richards, Kathryn H., Mankouri, J, Jamel Mankouri, Elliott, R.M., Wetherill Laura F., Fragkoudis, R., Richard M Elliott, Macdonald, Andrew, Harris, M, Wetherill, Laura F., Kohl Alain, Elliott Richard M., Macdonald Andrew, Wetherill, LF, Elliott, Richard Michael, Mark Harris, Harris, Mark, Fragkoudis, R, Kathryn H Richards, Fragkoudis, Rennos, Mankouri Jamel, Fragkoudis Rennos   +42 more
core   +1 more source

Anti-Influenza Protective Efficacy of a H6 Virus-Like Particle in Chickens

, 2020
H6 avian influenza viruses (AIVs) have a worldwide distribution, and they pose a potential concern for public health. In Taiwan, H6 AIVs have circulated in domestic chickens for more than 40 years, and certain strains have crossed the species barrier to ...
Wan-Zhen Zhu, Yi-Chi Wen, Ting-Chih Chen, Hui-Wen Chen, Shu-Yi Lin   +4 more
core   +1 more source

Advances in virus-like particle-based SARS-CoV-2 vaccines

Frontiers in Cellular and Infection Microbiology
The Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has incurred devastating human and economic losses. Vaccination remains the most effective approach for controlling the COVID-19
Xiaoting Hao, Feifei Yuan, Xuan Yao
doaj   +1 more source

Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity

Vaccines
Introduction: Dengue virus (DENV) remains a global health threat, with four distinct serotypes (DENV1-4) that complicate vaccine development due to low-affinity, cross-reactive antibodies that increase the risk of antibody-dependent enhancement (ADE ...
Dominik A. Rothen, Alessandro Pardini, Sudip Kumar Dutta, Pascal S. Krenger, Anne-Cathrine Vogt, Romano Josi, Monique Vogel, Paul Engeroff, Mona O. Mohsen, Kaspars Tars, Byron Martina, Martin F. Bachmann   +11 more
doaj   +1 more source

Development of a Ferritin Protein Nanoparticle Vaccine with PRRSV GP5 Protein

Viruses
Porcine reproductive and respiratory syndrome virus (PRRSV) presents a significant threat to the global swine industry. The development of highly effective subunit nanovaccines is a promising strategy for preventing PRRSV variant infections.
Xinjian Chang, Jun Ma, Yanrong Zhou, Shaobo Xiao, Xun Xiao, Liurong Fang   +5 more
doaj   +1 more source